A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 ResultsROCKSTROH, Jürgen K; DEJESUS, Edwin; FORDYCE, Marshall W et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 62, Num 5, pp 483-486, issn 1525-4135, 4 p.Article

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DFMARGOT, Nicolas A; ISAACSON, Erica; MCGOWAN, Ian et al.AIDS (London). 2002, Vol 16, Num 9, pp 1227-1235, issn 0269-9370Article

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patientsGALLANT, Joel E; WINSTON, Jonathan A; DEJESUS, Edwin et al.AIDS (London). 2008, Vol 22, Num 16, pp 2155-2163, issn 0269-9370, 9 p.Article

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patientsDEJESUS, Edwin; BERGER, Daniel; MCCOLL, Damian et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 1, pp 1-5, issn 1525-4135, 5 p.Article

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind studySCHOOLEY, Robert T; RUANE, Peter; MYERS, Robert A et al.AIDS (London). 2002, Vol 16, Num 9, pp 1257-1263, issn 0269-9370Article

Development of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Naïve Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934MARGOT, Nicolas A; ENEJOSA, Jeff; CHENG, Andrew K et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, Num 2, pp 209-221, issn 1525-4135, 13 p.Article

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients : 144-Week AnalysisARRIBAS, Jose R; POZNIAK, Anton L; TOOLE, John J et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 47, Num 1, pp 74-78, issn 1525-4135, 5 p.Article

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients : Virologic, immunologic, and morphologic changes-A 96-week analysisPOZNIAK, Anton L; GALLANT, Joel E; CHENG, Andrew K et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 5, pp 535-540, issn 1525-4135, 6 p.Article

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialDEJESUS, Edwin; ROCKSTROH, Jürgen K; CHENG, Andrew K et al.Lancet (British edition). 2012, Vol 379, Num 9835, pp 2429-2438, issn 0140-6736, 10 p.Article

Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical TrialZOLOPA, Andrew R; BERGER, Daniel S; LAMPIRIS, Harry et al.The Journal of infectious diseases. 2010, Vol 201, Num 6, pp 814-822, issn 0022-1899, 9 p.Article

Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adultsLAW, Matthew; PULS, Rebekah; CHENG, Andrew K et al.Antiviral therapy (London). 2006, Vol 11, Num 2, pp 179-186, issn 1359-6535, 8 p.Article

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virusDORE, Gregory J; COOPER, David A; POZNIAK, Anton L et al.The Journal of infectious diseases. 2004, Vol 189, Num 7, pp 1185-1192, issn 0022-1899, 8 p.Article